Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05508360

"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2)

This study will be a prospective, open-label, multi-center study including 72 patients that will collect additional safety and efficacy data for the Spinal Stabilization Technologies PerQdisc Nucleus Replacement System.

Recruiting

Interested in participating?

Request Info

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CIGE: Centro de Imunologia y Genetica, Medellín, Antioquia, Colombia

Loading trial locations.

About this study

This study will be a prospective, open-label, multi-center study that will collect additional safety and efficacy data for the minimally invasive PerQdisc Nucleus Replacement Device (NRD). Patients will have degenerative disc disease (DDD) in one or more lumbar discs. The NRD is used for surgical replacement of a single nucleus pulposus between spinal lumbar discs L1-S1 using any standard anterior, standard lateral, or minimally invasive posterolateral surgical approach. Currently the surgical gold standard involves spinal fusion of the affected vertebral bodies, reducing range of motion and increasing stress on other vertebral bodies. The goal of nucleus replacement is to reduce chronic low back pain by maintaining disc height while preserving range of motion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is skeletally mature aged 22-70.
  • Patient has Degenerative Disc Disease (DDD) at one or more levels between L1 and S1 but the discogenic pain must be limited to a single level.
  • Patient has adequate disc height (6mm) at the level to be treated
  • Patient has exhausted a minimum of 6 months of conservative treatment for their back (e.g. physical therapy, medications, injections, life style changes, etc).
  • Patient has a preoperative Oswestry Disability questionnaire score ≥ 40 out of 100 points (40/100)
  • Patient has a low back pain Visual Analog Scale (VAS) ≥ 40 mm (4 cm)
  • Patient has signed the approved Informed Consent Form.
  • All surgeries must be approved by the Medical Advisory Board (MAB)

Exclusion criteria

  • Patient has less than 6 mm of disc height.
  • Patient has had prior lumbar spine surgery (nucleoplasty at non-index level is considered acceptable).
  • Patient has had spinal fusion in the lumbar or thoracic intervertebral spaces. Cervical fusion is allowed as long as there are no neurologic deficits in the lower extremities.
  • Patient has spondyloarthropathy or other spondylolisthesis greater than 2 mm.
  • Patient has congenital moderate or severe spinal stenosis or epidural lipomatosis.
  • Patient has significant facet disease. Significant is defined as pain improvement of 80% or more following image-guided medial branch blocks of the target level according to SIS guidelines (diagnostic, contrast controlled).
  • Patient has any known active malignancy.
  • Patient has previously undergone or currently on immunosuppressive therapy. Steroids used to treat inflammation are allowed.
  • Patient has active or local systemic infection.
  • Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other autoimmune disease including AIDS, ARC and HIV.
  • Patient has diabetes mellitus (Type 1 or 2) requiring daily insulin management.
  • Patient has osteopenia of the spine (T-score of -1.0 or lower). A DEXA scan should be performed to rule out patients considered at risk for osteopenia.
  • Patient has morbid obesity defined as a body mass index (BMI) more than 40 or a weight of more than 45 kg (100 lbs.) over ideal body weight.
  • Patient has a known allergy to silicone or barium sulfate.
  • Patient has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.
  • Patient has a significant Schmorl's node in the level to be treated. Significant is defined as a large, rectangular or irregular shaped node that has an associated active inflammatory process (Modic I changes).
  • Patient has motion of less than 3 degrees on pre-operative lateral flexion/extension radiographs.
  • Patient belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally, disabled, prisoner, chronic alcohol/ substance abuser)

Intraoperative Exclusion Criteria:

  • Protrusion of the 20A Imaging Balloon up to or beyond the outer margin of the vertebra during the imaging steps.
  • Patient has a violated endplate as determined by imaging balloons during fluoroscopy.
  • Patient has a disc space that is too narrow for implantation. MIPL Specific
  • Poor radiological visualization of Kambin's triangle.
  • Sustained irritation of the exiting nerve root during any aspect of the annular dilation technique (leg movement or if performing with electrical monitoring) in spite or repositioning instruments.

Treatment and study plan

PerQdisc Nucleus Replacement System

Device

Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.

Primary outcomes

  1. Perfromance: ODI

    Time frame: 6 months

    Change in in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient-reported outcome tool

  2. Perfromance: ODI

    Time frame: 12 months

    Change in in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient-reported outcome tool

  3. Performance: VAS

    Time frame: 6 months

    Change in back pain as measured by the 100 - millimeter Visual Analog Scale (VAS)

  4. Performance: VAS

    Time frame: 12 months

    Change in back pain as measured by the 100 - millimeter Visual Analog Scale (VAS)

  5. Safety: Expulsion & Device Failure

    Time frame: 6 months

    Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's

  6. Safety: Expulsion & Device Failure

    Time frame: 12 months

    Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's

Secondary outcomes

  1. Safety: Revision Surgery

    Time frame: 6 months, 12 months, and 5 years

    Incidence of revision surgery

  2. Safety: Expulsion & Device Failure

    Time frame: 5 years

    Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's

  3. Performance: Disc Height

    Time frame: 6 months, 12 months, and 5 years

    Preservation of intervertebral disc height (in mm) as measured on MRI post-surgery compared to baseline

  4. Performance: RoM

    Time frame: 6 months, 12 months, 5 years

    Preservation of range of movement (expressed in degrees) at the index and adjacent levels at baseline compared to follow-up using flexion/extension radiographs

  5. Safety: Neurological Status

    Time frame: 6 months, 12 months, and 5 years

    Maintenance of baseline neurologic status through physical assessment evaluating nerve compression at baseline and post-surgical follow-up using pain, motor strength, and sensation feedback from the patient on a 0 (no compression) to 5 (major compression) scale

  6. Performance: Analgesic Score

    Time frame: 6 months, 12 months, and 5 years

    Change in level of pain medication used comparing baseline to follow up visits based on a medication scale ranging from 0 (no meds) - 4 (high dose opioids)

  7. Safety: SAE

    Time frame: 6 months, 12 months, and 5 years

    Incidence of serious adverse events that are related to the surgical procedure or Incidence of Serious Adverse Events related to the surgical procedure or device

Study contacts

Contact information is provided by the study sponsor or research team.

Maren Lange

CONTACT

[email protected]

8004841588

Molly Bond

CONTACT

[email protected]

1 (715) 577-7527

Sponsors and collaborators

Lead sponsor

Spinal Stabilization Technologies

Industry

Registry information

Acronym: LOPAIN2

Important dates

Study start
2022
Primary completion
2027
Study completion
2030
First posted
Aug 19, 2022
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.